Zacks: Analysts Set $15.50 Target Price for Checkpoint Therapeutics Inc (CKPT)

Checkpoint Therapeutics Inc (NASDAQ:CKPT) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Brokers have set a one year consensus price objective of $15.50 for the company and are expecting that the company will post ($0.27) EPS for the current quarter, according to Zacks. Zacks has also given Checkpoint Therapeutics an industry rank of 184 out of 265 based on the ratings given to its competitors.

Several equities research analysts have commented on CKPT shares. Zacks Investment Research raised shares of Checkpoint Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a report on Thursday, November 23rd. HC Wainwright started coverage on shares of Checkpoint Therapeutics in a report on Friday, December 8th. They issued a “buy” rating and a $11.00 price target on the stock.

Checkpoint Therapeutics (NASDAQ CKPT) traded down $0.11 during trading hours on Monday, reaching $4.13. 16,974 shares of the company’s stock traded hands, compared to its average volume of 46,870. Checkpoint Therapeutics has a one year low of $3.20 and a one year high of $15.00. The stock has a market capitalization of $103.35 and a price-to-earnings ratio of -3.69.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Set $15.50 Target Price for Checkpoint Therapeutics Inc (CKPT)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.

Get a free copy of the Zacks research report on Checkpoint Therapeutics (CKPT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply